Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2019

View Archived Issues

Improbability research yields path to HIV vaccine

Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study

Phase I data presented for the novel M1 mAChR modulator VU-319

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

EGFL7 as a new therapeutic target in AML

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer

Soligenix initiates phase Ic study of RiVax

Kaleido to advance KB-174 for HE based on topline data from study in patients with cirrhosis

First phase III data for YF-H-2015005 shows rapid mobilization of CD34+ cells

New long-acting HIV-1 fusion inhibitor-based regimen developed

DPP8 may be a target for multiple myeloma therapy by inducing apoptotic cell death

Antabio SAS patents new antibacterial compounds

Adlai Nortye divulges new CSF1R inhibitors

Innovent Biologics presents PI3K inhibitors

DYRK2 is a critical checkpoint in the control of leukemia stem cell maintenance

Merck & Co. describes new IDO1 inhibitors

Study confirms target engagement with BTRX-335140 in healthy volunteers

C&C Research Laboratories identifies STAT3 inhibitors

OrphoMed begins phase II study of ORP-101 in IBS-D

New phase II trial investigates CFZ-533 in pediatric and young adults with type 1 diabetes

Phase III study of Tecentriq with Cotellic and Zelboraf in melanoma meets primary endpoint

Phase II study of TG-4010 combination regimen in advanced NSCLC fails to meet primary endpoint

FDA grants accelerated approval to Vyondys 53 for DMD in patients amenable to skipping exon 53